Designing Longevity
Skip to main content

Sexual Health and Fertility Peptide Evidence

The clearest evidence concerns specific medical uses. Vyleesi treats a defined low-desire disorder, while ganirelix and cetrorelix serve a different purpose during IVF. Kisspeptin and intranasal oxytocin studies answer narrower research questions.

Sources reviewed November 13, 2026 · How we work

Bremelanotide (PT-141) and low sexual desire

The FDA reviewed Vyleesi as a specific bremelanotide injection for premenopausal women with acquired, generalized HSDD. The trials measured desire and distress. The groups did not differ significantly in the number of satisfying sexual experiences, a separate measure.

Sources for this section

Ganirelix and cetrorelix during IVF

Ganirelix acetate and cetrorelix acetate block the action of gonadotropin-releasing hormone, a signal that can lead to early ovulation. Their labels describe prevention of a premature hormone surge during monitored ovarian stimulation. The labels answer an IVF timing question. A fertility clinic can explain how that fits the overall chance of a live birth for the individual cycle.

Sources for this section

Kisspeptin-54 for sexual desire and egg maturation

In a small randomized study, 32 premenopausal women with HSDD completed visits with kisspeptin-54 given by vein and with placebo. The primary measures were brain responses to sexual and attraction cues during the visits. The study found differences in brain activity and some self-reported responses. Whether repeated treatment produces lasting relief in daily life remains open.

A separate phase 2 study used kisspeptin-54 as an egg-maturation trigger in IVF patients at high risk of ovarian hyperstimulation, an excessive response to fertility medicines. It studied mature eggs in a closely monitored fertility clinic. These experiments used kisspeptin-54. FDA has raised potential safety concerns about compounded formulations containing the shorter kisspeptin-10, including possible immune reactions and impurities.

Sources for this section

Oxytocin claims and what is actually in the product

A randomized study of intranasal oxytocin in women with sexual dysfunction found similar improvements over time with oxytocin and placebo. It provides little basis for expecting a marketed oxytocin spray to improve sexual function.

Check whether a claim refers to the exact finished product and route studied. An approved prescription product has a specific label, strength and form. FDA does not approve compounded products or verify their safety, effectiveness or quality before marketing. FDA has also cited sellers for marketing unapproved bremelanotide despite research-use-only labeling.

Sources for this section
Explore Sexual Health & Fertility